| TAH Drug Code | OOLM |
|---|---|
| Indications | Hypertension: Treatment of hypertension with or without concurrent use of other antihypertensive agents |
| Dosing | HTN: initial 20mg QD, after 2weeks may titrate up to 40mg QD. |
| Hepatic Impairment | Dose adjustment not necessary |
| Renal Impairment | Dose adjustment not necessary |
| Contraindications | Concomitant use with aliskiren in patients with diabetes mellitus Canadian labeling: Additional contraindications (not in U.S. labeling): Hypersensitivity to olmesartan or any component of the formulation; concomitant use with aliskiren in patients with moderate to severe renal impairment (GFR <60 mL/minute/1.73 m2) |
| Adverse Effects | 1% to 10%: Central nervous system: Dizziness, headache Endocrine & metabolic: Hyperglycemia, hypertriglyceridemia Gastrointestinal: Diarrhea Neuromuscular & skeletal: Back pain, CPK increased Renal: Hematuria Respiratory: Bronchitis, pharyngitis, rhinitis, sinusitis Miscellaneous: Flu-like syndrome |
| Pregnancy | Human Data Suggest Risk in 2nd and 3rd Trimesters |
| Lactation | No (Limited) Human Data - Probably Compatible |
| More Info | UpToDate |